What's Happening?
Parse Biosciences has announced a new FFPE-compatible barcoding technology that enables whole transcriptome single cell analysis from archived tissue samples. This breakthrough allows researchers to perform
single cell RNA sequencing on formalin-fixed, paraffin-embedded samples, overcoming previous limitations due to RNA degradation. The technology uses a novel split-pool combinatorial barcoding method, providing high-resolution transcriptomic data without relying on predefined gene lists. This advancement is expected to significantly enhance research in oncology, translational medicine, and precision medicine.
Why It's Important?
The introduction of FFPE-compatible barcoding technology by Parse Biosciences represents a major advancement in single cell analysis. By enabling comprehensive transcriptome analysis from archived samples, researchers can access valuable data that was previously unattainable. This technology has the potential to accelerate discoveries in cancer research, tissue repair, and other areas of medical science. It could lead to more precise and personalized treatment options, improving patient outcomes and advancing the field of precision medicine.
What's Next?
Parse Biosciences is currently conducting early-access testing with select customers and plans a broader release in the first quarter of 2026. The company will collaborate with partners to refine the technology and ensure its effectiveness in various research applications. As the technology becomes more widely available, it is expected to drive innovation in single cell analysis and expand the possibilities for translational research. Researchers and institutions will likely explore new applications and methodologies, further advancing the field.
